SNOA

Dopo l'orario di chiusura: 1.34

Sonoma Pharmaceuticals Inc (SNOA)

Panoramica Notizia Cronologia dei prezzi Financials Perché SNOA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile

Sonoma Pharmaceuticals Inc

Healthcare (1033)

800-759-9305

5445 CONESTOGA COURT, SUITE 150, BOULDER, CA

Prossima data di guadagno

Ultimi documenti SEC

SNOA's Discussions on Twitter

Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SNOA Sonoma Pharmaceuticals Inc	1.34	6.42M	19.53M	-3.18M	-4.13M	-1.888
TAK Takeda Pharmaceutical Co Adr	18.24	57.90B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.16	43.41B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	36.93	42.89B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.17	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	512.88	22.35B	3.17B	1.29B	1.01B	27.09

Sonoma Pharmaceuticals Inc Borsa (SNOA) Ultime notizie

Sonoma Pharmaceuticals Inc Azioni (SNOA) Dati Finanziari

Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile

Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR

Sonoma Pharmaceuticals Inc Borsa (SNOA) Ultime notizie

Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com South Africa

Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting - TipRanks

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum - Investing.com

Price to earnings forward of Sonoma Pharmaceuticals, Inc. – SWB:O8Z - TradingView

Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Nigeria

Sonoma Pharmaceuticals reports 60% revenue growth in Q1 - Investing.com

Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive - TradingKey

Sonoma Pharmaceuticals Q1 revenue rises on US growth - TradingView

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Bay to Bay News

BRIEF-Sonoma Pharmaceuticals Q1 Operating Expenses USD 2.6 Million - TradingView

Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan

Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary - TradingView

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - TradingView

Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsStop Loss Guidance - dars.gov.et

SNOA Q1'26 Earnings: EPS estimate is (0.30) USD - TradingView

SNOA Q2 2026 Earnings: Narrow EPS Miss Weighs on SharesROE Trend Analysis - Vinanet

Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com South Africa

Sonoma Pharmaceuticals (SNOA) Hovers Near Support as Slight Decline ContinuesRVOL Breakout - vinanet.vn

Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Sonoma Pharmaceuticals Inc - TradingKey

SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020 - TradingKey

Sonoma Pharmaceuticals (SNOA) Slides 1.72% as Stock Holds Above Key Support at $1.08Negative Gamma - vinanet.vn

TradingKey - TradingKey

SNOA Q2 2026 Earnings: Slight EPS Miss, Stock Edges LowerProfit Warning Alert - vinanet.vn

SNOA Q2 2026 Earnings: EPS Misses Estimates; Stock Rises Amid Operational UpdatesCFO Commentary Report - Vinanet

19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026. - marketscreener.com

Sonoma Pharmaceuticals (SNOA) Edges Higher as Volume Patterns Suggest Accumulation Near Key SupportAAII Bearish - dars.gov.et

Sonoma Pharmaceuticals (SNOA) Slips 4.21% as Stock Tests Key Support LevelsVWAP Bounce - vinanet.vn

Sonoma Pharmaceuticals (SNOA) Holds Steady at $1.26 as Consolidation ContinuesInside Day Breakout - dars.gov.et

Enterprise value to revenue forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView

Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa

Price to sales forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView

Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan

Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView

Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView

Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView

SNOA Should I Buy - Intellectia AI

Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus

Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com

Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire

Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView

Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

SNOA Q1 2026 Earnings: EPS Misses Estimates by 1.2%, No Revenue Reported, Stock Edges Up 0.87% - po-news-eg.net

Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail

Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart

According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget

Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK

Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria

Sonoma Pharmaceuticals Inc Azioni (SNOA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a SNOA